PHIO Phio Pharmaceuticals Corp.
Healthcare$1.11+0.00%OpenMarket Cap: $12.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.77
P/S
0.00
EV/EBITDA
0.38
DCF Value
$3.45
FCF Yield
-84.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-77.3%
ROA
-62.8%
ROIC
-67.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-4.2M | $-4.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-2.5M | $-2.4M | $— | — |
| FY null | $0.00 | NaN% | $-9.2M | $-8.7M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.5M | $-2.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-2.3M | $-2.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.9M | $-1.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.7M | $-1.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-7.4M | $-7.2M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-1.6M | $-1.5M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-1.9M | $-1.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.2M | $-2.2M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.8M | $-1.9M | $-4.56 | — |